Stocks · News reference

MiNK Therapeutics Says First Patients Treated With agenT-797 In Phase 2 Severe Hypoxemic Pneumonia Trial Alive At Day 28 With Improved Oxygenation, Infection Control

Aug 6, 2026, 4:09 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 13, 2026, 1:29 PMBenzinga Insights
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript
MiNK Therapeutics (NASDAQ:INKT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to
INKT
SEC EDGARAug 13, 2026, 11:40 AMSEC EDGAR
8-K filing — MiNK Therapeutics, Inc. (INKT)
Filed: 2026-08-13 AccNo: 0001193125-26-347907 Size: 215 KB Item 2.02: Results of Operations and Financial Condition
INKT
BenzingaAug 13, 2026, 11:33 AMBenzinga Newsdesk
MiNK Therapeutics Announces Launch Of Paid International Named-Patient Access Program For agenT-797 In Brazil With Orphan Drug Consulting
INKT
BenzingaAug 13, 2026, 11:33 AMBenzinga Newsdesk
MiNK Therapeutics Says First Patients In Randomized Phase 2 C-1300-02 Trial Of agenT-797 Alive At Day 28 With Improved Oxygenation, ARDS Resolution, Vasopressor Liberation
INKT